Veraxa provides a platform for creating next‑generation antibody‑drug conjugates and BiTAC bispecific formats that combine high‑throughput droplet microfluidic antibody discovery with site‑specific bioconjugation using genetic code expansion and click chemistry. The technology yields homogeneous, stable ADCs and conditionally activated bispecifics with defined drug‑to‑antibody ratios, aiming to improve efficacy and safety for oncology therapeutics.
Funding
$3.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antibody‑drug conjugates (ADCs) and bispecific antibodies often exhibit narrow therapeutic windows, leading to significant off‑target toxicity and limited efficacy, especially in solid tumors and in patients who cannot tolerate intensive chemotherapy.
Solution
Veraxa develops next‑generation antibody‑based cancer therapeutics that combine advanced antibody discovery with proprietary bioconjugation technologies. Their platform uses high‑throughput droplet microfluidics to screen entire immune repertoires for functional, internalizing antibodies, and genetic code expansion to place payloads at precise sites on the antibody. Bioorthogonal click chemistry then creates homogeneous ADCs or BiTAC formats with defined drug‑to‑antibody ratios and stable C‑C linkages. The BiTAC architecture splits a bispecific molecule into two complementary halves that only reconstitute on tumor cells, providing combinatorial‑gated activation and reducing off‑tumor toxicity. Together, these innovations aim to deliver cancer therapies with higher efficacy, broader therapeutic windows, and fewer side effects across multiple indications.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology therapeutics, as well as academic research groups seeking advanced antibody discovery and bioconjugation capabilities.
Features
- Droplet‑based microfluidic screening platform that identifies antibodies with internalization, agonistic or antagonistic receptor modulation in a single high‑throughput assay
- Genetic code expansion technology enabling precise, site‑specific incorporation of clickable amino acids anywhere in the antibody sequence
- Proprietary bioorthogonal click chemistry that produces uniform ADCs with stable C‑C bonds and controlled drug‑to‑antibody ratios
- BiTAC platform that splits bispecific antibodies into two precursors, achieving conditional activation only when both bind adjacent tumor antigens
- Integrated workflow combining functional antibody selection, positional payload engineering, and efficient conjugation to accelerate ADC and BiTAC development
- Modular payload library with hydrophilic tetrazine‑functionalized toxins to improve pharmacokinetics and safety